Research Highlight

A Peptide-Antibody Hybrid Platform for Targeted Cancer Therapy

Synergy in hybrid-A new hybrid platform is developed based on a hapten-labeled bispecific peptide and an anti-hapten antibody to overcome the short plasma half-life of most peptide therapeutics....read more